2025 International Congress

October 5-9, 2025. Honolulu, Hawaii.

View by Title View Categories

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

Vagus nerve ultrasound and its association with non-motor symptoms in parkinson’s disease

S. Garcia, J. Sanchez, J. Grandas (MADRID, Spain)
Valbenazine Improves Chorea Across Multiple Body Regions in Adults With Huntington’s Disease

E. Furr Stimming, E. Kayson, R. Mehanna, J. Goldstein, S. Hinton, O. Klepitskaya, H. Zhang, D. Haubenberger (Houston, USA)
Valbenazine Improves the Burden and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO Study

E. Dunayevich, A. Parameswaran, M. Bron, E. Franey, D. Sparta, C. Zeng, S. Mathias, J. Mcevoy (San Diego, USA)
Validating Real-World Evidence for Identifying Adverse Events Related to a Deep Brain Stimulation Implant

J. Joseph, Y. Pathak, C. Salazar, A. Benison (Plano, USA)
Validation of a quantitative test using kinesiological evaluation of upper extremity movements in patients with Parkinson’s disease: A pilot study.

A. Castillo-Ivon, A. Montes-Ugalde, V. Bueyes-Roiz, C. Hernandez-Arenas, P. Velasco-Acosta, L. Anaya-Campos, I. Quiñones-Uriostegui, J. Quinzaños-Fresnedo (Mexico City, Mexico)
Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body

M. Kurihara, T. Matsubara, K. Satoh, A. Arakawa, M. Hara, K. Kanemaru, A. Iwata, S. Murayama, Y. Saito (Tokyo, Japan)
Validation of the Short Progressive Supranuclear Palsy Quality of Life Scale in PSPNI

Q. Shen, XY. Li, J. Wang, FT. Liu (Shanghai, China)
Value of local field potential-based deep brain stimulation programming in Parkinson’s disease

C. Gonzalez-Robles, J. Candelario-Mckeown, C. Duraffourd, M. Krueger, M. Mancuso, L. Mooney, H. Akram, J. Hyam, T. Foltynie, S. Xu, L. Zrinzo, P. Limousin (London, United Kingdom)
Variations of Self-Perceived Cognitive Changes by Ethnicity in Parkinson’s Disease Patients

H. Lee, P. Parekh, A. Arroyo, I. Balbo, A. Fanning, R. Alcalay, J. Agin-Liebes (New York, USA)
Ventral and Dorsal Language Pathways in Patients with Lewy Bodies: an fMRI Study of Syntactic Sentence Processing

L. Novakova, M. Gajdos, D. Carbol, I. Rektorova (Brno, Czech Republic)
VGN-R09b, an Adeno-associated virus-based Combination Gene Replacement Therapy for Parkinson’s Disease

YZ. Tao, SS. Tian, L. Lu, X. Zhu, H. Lv, XP. Zhao (Shanghai, China)
Vibrotactile Stimulation with Cueing as Promising Therapeutic Approach in Orthostatic Tremor.

V. Azoidou, A. Zirra, T. Boyle, D. Gallagher, A. Noyce, C. Simonet (London, United Kingdom)
Virtual Gait Lab: Assessment of Freezing of Gait in Parkinson’s Disease Using Virtual Reality

K. Seo, M. Hara, S. Alaoui, S. Emoto, T. Ishii, K. Abe, G. Oyama, T. Yamamoto (Saitama, Japan)
Virtual Reality Boxing Program for Individuals with Parkinson’s Disease; A Quality Improvement Project.

F. Jamal, D. Padilla (Houston, USA)
Virtual Reality to Assess for Digital Biomarkers of Visual Hallucinations in Parkinson’s Disease

K. Getchell, S. Hirczy, A. Lin (Seattle, USA)
Vision in Motion: Eye Exercises to Enhance Balance in Parkinson’s Disease – A Randomized Controlled Trial

MA. Tabibi, A. Chitsaz, F. Nazemi, N. Salimian (Isfahan, Islamic Republic of Iran)
Visual processing impairments are predictive of dementia in Lewy Body disease

E. Mccann, F. Coleman, A. Fazlollahi, S. Lee, J. O'Sullivan, P. Nestor (Herston, Australia)
Vitamin D3 Supplementation Ameliorates Non-Motor Symptoms Associated with Parkinson’s Diseases in a Rotenone Model in Wistar Rats

A. Bayo-Olugbami, N. Oseni, P. Jimoh, L. Anifowose, B V. Owoyele (Osogbo, Nigeria)
Voluntariness in painful legs moving toes: insights form neurophysiological studies

J. Chen, T. Grippe, C. Ganos, R. Chen (Toronto, Canada)
VPS13C: a Modifier Gene causing Suboptimal Response to Levodopa in Early-Onset Parkinson’s Disease

L. Malfer, C. Piat, O. Ross, Z. Niu, E. Benarroch, R. Savica (Jacksonville, USA)
VPS35-Related Parkinson Disease in a Patient of Korean Ancestry: A Case Report

B. Yasuda, M. Bruno (Honolulu, USA)
VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease

M. Facheris, D. Ysselstein, J. van Dervalk, E. Thijssen, L. Pagan, G. Valstar, C. Schotborgh, P. Kremer, M. Hagey, J. Cederbaum, J. Sullivan, K. Hunt, O. Siddiqui (Chicago, USA)

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z